Guillaume Mestrallet
@gmestrallet.bsky.social
Researcher in Immuno-oncology
We're excited to share our latest work: "Targeting neoantigens conserved across organs and species overcomes tumor immune escape"!
Thanks to the team at @sinaiimmuno.bsky.social !
www.biorxiv.org/content/10.1...
Thanks to the team at @sinaiimmuno.bsky.social !
www.biorxiv.org/content/10.1...
Targeting neoantigens conserved across organs and species overcomes tumor immune escape
Neoantigen-targeted immunotherapies hold promise for cancer treatment, but current personalized approaches are time-consuming and costly. Here, we identify neoantigens encoded by Ptprs and Igf2r that ...
www.biorxiv.org
September 29, 2025 at 12:24 PM
We're excited to share our latest work: "Targeting neoantigens conserved across organs and species overcomes tumor immune escape"!
Thanks to the team at @sinaiimmuno.bsky.social !
www.biorxiv.org/content/10.1...
Thanks to the team at @sinaiimmuno.bsky.social !
www.biorxiv.org/content/10.1...
@francoisrousset.bsky.social will give a talk at Mount Sinai Hospital on May 7th. If interested, please do not hesitate to reach out!
April 15, 2025 at 4:52 PM
@francoisrousset.bsky.social will give a talk at Mount Sinai Hospital on May 7th. If interested, please do not hesitate to reach out!
Glad to share our work about resistance to immunotherapy! We discovered a combination therapy allowing to eliminate 100% of MMRd CRC tumors and >70% or MMRp CRC tumors. We also identified the T cell and macrophage subsets mediating the response. Thanks to the team! www.biorxiv.org/content/10.1...
February 18, 2025 at 3:45 PM
Glad to share our work about resistance to immunotherapy! We discovered a combination therapy allowing to eliminate 100% of MMRd CRC tumors and >70% or MMRp CRC tumors. We also identified the T cell and macrophage subsets mediating the response. Thanks to the team! www.biorxiv.org/content/10.1...